| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 631 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | ALEC Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | Sell | 1,820 | $2.65 | $4,823.00 | -1.7% | |
| Apr 16, 2026 | AURA Aura Biosciences, Inc. | Kilroy Conor | See Remarks | Sell | 11,738 | $7.02 | $82,400.76 | -5.1% | |
| Apr 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | Baroldi Joseph52 | EVP, Chief Business Officer | Sell | 5,619 | $74.56 | $418,952.64 | -10.8% | |
| Apr 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | Jenne Kyle | EVP, Chf Gl Pdt Str Ofcr | Sell | 4,902 | $75.17 | $368,488.24 | -17.1% | |
| Apr 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | Birchler Brian52 | EVP, Corp And Development Ops | Sell | 973 | $75.04 | $73,015.87 | -1.4% | |
| Apr 16, 2026 | SION Sionna Therapeutics, Inc. | Thompson Peter A.65 | Director | Sell | 510,583 | $44.94 | $22,945,043.50 | -5.0% | |
| Apr 16, 2026 | ADPT Adaptive Biotechnologies Corporation | Rubinstein Julie84 | President And COO | Sell | 57,180 | $14.45 | $826,251.00 | -4.4% | |
| Apr 16, 2026 | SION Sionna Therapeutics, Inc. | Orbimed Advisors LLC67 | Director | Sell | 510,583 | $44.94 | $22,945,043.50 | -5.0% | |
| Apr 15, 2026 | ACIU Ac Immune SA | Pfeifer Andrea | Chief Executive Officer | Sell | 10,000 | $3.14 | $31,425.00 | -0.3% | |
| Apr 15, 2026 | ORKA Oruka Therapeutics, Inc. | Goncalves Joana90 | Chief Medical Officer | Sell | 7,000 | $66.12 | $462,829.56 | -6.3% | |
| Apr 15, 2026 | VANI Vivani Medical, Inc. | Williams Gregg75 | Director, 10% Owner | Buy | 1,587,301 | $1.26 | $1,999,999.26 | +5.1% | |
| Apr 15, 2026 | IONS Ionis Pharmaceuticals, Inc. | Parshall B Lynne74 | Director | Sell | 5,000 | $76.27 | $381,366.52 | -4.6% | |
| Apr 15, 2026 | GILD Gilead Sciences, Inc. | Mercier Johanna | Chief Comm &Corp Aff Officer | Sell | 3,000 | $140.96 | $422,880.00 | -2.3% | |
| Apr 15, 2026 | SEPN Septerna, Inc. | Bhatt Elizabeth | President And COO | Sell | 4,000 | $24.34 | $97,343.36 | -0.8% | |
| Apr 15, 2026 | CYTK Cytokinetics, Incorporated | Blum Robert I51 | President &CEO | Sell | 7,500 | $65.38 | $490,350.00 | -1.8% | |
| Apr 15, 2026 | CYTK Cytokinetics, Incorporated | Callos Andrew | EVP, Chief Commercial Officer | Sell | 7,449 | $66.02 | $491,782.98 | -11.3% | |
| Apr 15, 2026 | GILD Gilead Sciences, Inc. | Dickinson Andrew D | Chief Financial Officer | Sell | 3,000 | $140.96 | $422,880.00 | -1.7% | |
| Apr 15, 2026 | ACIU Ac Immune SA | Pfeifer Andrea | Chief Executive Officer | Buy | 10,000 | $3.14 | $31,425.00 | +0.3% | |
| Apr 15, 2026 | KYMR Kymera Therapeutics, Inc. | Chadwick Jeremy G | Chief Operating Officer | Sell | 6,551 | $90.00 | $589,598.40 | -5.1% | |
| Apr 15, 2026 | VOR Vor Biopharma Inc. | Ra Capital Management, L.P.53 | Director, 10% Owner | Sell | 737,989 | $16.10 | $11,883,339.89 | -7.0% | |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | Cline Christopher R.50 | Chief Financial Officer | Sell | 8,327 | $41.91 | $348,974.00 | -1.7% | |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | Inrig Jula45 | Chief Medical Officer | Sell | 8,233 | $42.01 | $345,893.27 | -3.5% | |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | Dube Eric M57 | Chief Executive Officer | Sell | 64,000 | $41.09 | $2,629,975.10 | -4.7% | |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | Reed Elizabeth E58 | Chief Legal Officer And GC | Sell | 51,500 | $41.29 | $2,126,451.68 | -10.4% | |
| Apr 15, 2026 | MLYS Mineralys Therapeutics, Inc. | Rodman David Malcom56 | Chief Medical Officer | Sell | 20,406 | $26.89 | $548,672.35 | -12.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.